Dr. Samantha Pulliam describes the leva Pelvic Health System

Functional success was achieved in 58% of patients at 5-year follow-up.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

The approval of vibegron is supported by data from the phase 3 COURAGE trial.

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

The primary aims for the EVANESCE-II trial are to confirm the safety of the FemPulse System and to establish noninferiority to first-line tolterodine.

The UUI responder rate was 71.8% among those who received SNM and 71.3% among those who received iTNM.